Please provide your email address to receive an email when new articles are posted on . Five factors were identified as reasons why patients avoid treatment with adalimumab and other biologics.

Biologics remain viable options with varying persistence over 1 year in patients with inflammatory bowel disease.

Bimekizumab exhibited superior drug survival rates among patients with psoriasis who have previously stopped responding to at ...

One biologic, adalimumab, is currently approved to treat hidradenitis suppurativa. Adalimumab works by targeting a specific inflammation pathway involved in the condition. Hidradenitis suppurativa (HS ...

Posters presented at the American Academy of Dermatology Annual Meeting identified significant undertreatment of psoriasis and significant gaps in biologic medication treatment. This content was ...

Biologic treatment costs for plaque psoriasis more than doubled from 2007 to 2021, despite cheaper alternatives. Switching to the lowest-cost biologic in each class could reduce treatment costs by 44% ...

A new study published in the Journal of American Medical Association showed that psoriasis patients who used antibiotics had ...

CORRECTED April 15, 2024 // An earlier version of this article stated incorrect percentages of patients who never received any biologics during the study's 3-year period but improved rapidly or ...

Eczema can be managed with certain self-care regimens, such as fragrance-free soap, brief lukewarm baths or showers, and regular skin hydration with a strong emollient like CeraVe cream or Vaseline.

SAN ANTONIO -- Patients with asthma at one large academic medical center were not prescribed a biologic therapy very often over a 5-year period, a researcher reported, although patient adherence to a ...